Research programme: protein kinase inhibitors - Novartis/Vertex

Drug Profile

Research programme: protein kinase inhibitors - Novartis/Vertex

Alternative Names: VX-322; VX-398; VX-608

Latest Information Update: 24 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Novartis; Vertex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Protein kinase inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cardiovascular disorders; Inflammation; Neurological disorders

Most Recent Events

  • 17 Nov 2004 Novartis has selected VX 322 for clinical development
  • 10 Feb 2004 Vertex and Novartis amend research agreement
  • 26 May 2000 Preclinical development for Cardiovascular disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top